I in vitro- forøg har man set, at tipranavir hæmmer trombocytaggregationen ved koncentrationer på niveau med de koncentrationer, der ses hos patienter i APTIVUS/ ritonavir behandling.
In in vitro experiments, tipranavir was observed to inhibit human platelet aggregation at levels consistent with exposures observed in patients receiving APTIVUS/ ritonavir.